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ABSTRACT 
Objective: The present study was carried out to investigate the in vitro anti-inflammatory activity of syringic acid (SA).  
Methods: SA was tested for it's in vitro anti-inflammatory activity at different concentrations in protein denaturation, proteinase inhibition and 
human red blood cell (HRBC) membrane stabilization assay. The reference drugs used were aspirin and diclofenac sodium. 
Results: SA showed concentration-dependent inhibition of protein denaturation and proteinase activity with a half-maximal inhibitory 
concentration (IC50) value of 49.38±0.56 µg/ml and 53.73±0.27 µg/ml respectively. Heat-induced haemolysis was inhibited by SA with an IC50 value 
of 57.13±0.24 µg/ml. SA also inhibited the hypotonicity-induced haemolysis (IC50 
Conclusion: From the present study, we can conclude that SA possesses appreciable anti-inflammatory effect against denaturation of proteins, 
proteinase activity, and human red blood membrane stabilization assays. Further studies are required for determining the possible mechanisms 
behind its anti-inflammatory action. 
value of 53.87±0.72 µg/ml). 
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Inflammation is the protective mechanism present in the body 
against injury or damage. In case of an injury to a particular tissue, 
the adjacent tissues take part in the process of inflammation, to heal 
the affected tissue. There are a number of agents that may damage 
or kill the cells, such as trauma, heat, cold, radiation, certain 
chemicals like acids or organic poisons such as paraquat. 
Inflammation may be caused by the invasion of immunological 
agents and microbes such as bacteria, viruses, and parasites [1]. 
The release of chemical mediators like prostaglandins, histamine, 
serotonin, kinins, and cytokines present at the site of injury is 
responsible for triggering the inflammatory response. These 
mediators are known as biological messengers that act on the 
inflammatory cells and contribute to the development of the 
inflammatory response. The complex process of inflammation involves 
an increase in the vascular permeability, denaturation of proteins and 
alteration in the membrane stability of the injured cells [2].  
Inflammation can be grouped as acute or chronic, depending on the 
severity of the condition. Acute inflammation is one that involves 
only the initial stages of the process marked by the exudation of 
plasma and white blood cells from the blood to the site of injury. In 
cases, where the causative agent of inflammation is not successfully 
removed, the acute inflammation is then followed by chronic 
inflammation [2]. 
The current regime for the management of inflammation includes 
the administration of the non-steroidal anti-inflammatory drugs 
(NSAIDs), glucocorticoids and opioids. These therapies suffer from 
the drawback of long-term toxicity and variation in clinical efficacy 
[3]. Syringic acid (SA) (4-hydroxy-3,5-dimethoxybenzoic acid) is a 
polyphenolic compound (fig. 1) found in abundance in olives, dates, 
spices, pumpkin, grapes, acai palm, honey, and red wine. SA is also 
present in large quantities in plants namely, Annona squamosa, 
Catunaregam, Raphanus sativus, Hemidesmus indicus and Tagetes 
erecta Linn flower [4]. SA has previously shown to possess strong 
antioxidant properties along with neuroprotective, hepato-
protective, anti-angiogenic, anti-steatotic, anticancer and anti-
osteoporotic activities [5-12]. 
Extracts of a number of plants containing SA have demonstrated anti-
inflammatory activity [4]. A survey of the literature showed that no 
systematic approach was undertaken to evaluate the anti-inflammatory 
potential of SA in vitro. The aim of the present study was to evaluate the 
anti-inflammatory potential of SA by assessing its effect on protein 
denaturation, proteinase activity, and membrane stabilization assays. 
 
 
Fig. 1: Structure of syringic acid 
 
MATERIALS AND METHODS 
Drugs and chemicals 
Syringic acid was purchased from Tokyo Chemical Industry Ltd. 
(Mumbai, India). Diclofenac sodium and aspirin were procured from 
SD Fine Chemicals Ltd. (Mumbai, India). The other chemicals were 
obtained from commercial sources and were of analytical grade. 
In vitro anti-inflammatory activity 
Protein denaturation assay 
The assay was performed according to the procedure described 
previously with slight modifications [13]. The reaction mixture 
prepared consisted of 1 ml of SA at different concentrations (table 
1), to which 1 ml of 1% bovine serum albumin was added. The pH of 
the reaction mixture was adjusted to 7.4, and the mixture was 
incubated at room temperature for 20 min. This was followed by 
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heating at 56 °C for 20 min. The samples were left to cool to room 
temperature and the turbidity developed was measured 
spectrophotometrically at 660 nm. The samples were prepared in 
triplicates.  
Percentage inhibition of protein denaturation was calculated by: 
[(Ac − At) (Ac)]⁄  × 100 
Where Ac denotes the absorbance of the control and At denotes the 
absorbance of the test sample. 
Proteinase inhibition assay 
The test was performed according to the method provided in the 
literature with minor modifications [13, 14]. To 100 µl of the test 
sample prepared at varying concentrations (table 1), was added 100 
µl of 1% bovine serum albumin and the reaction mixture was 
incubated at room temperature for 5 min. 250 µl of trypsin was 
added, followed by centrifugation. The absorbance of the 
supernatant was noted at 210 nm using a UV-visible spectro-
photometer. The samples were prepared in triplicates. 
Percentage inhibition of proteinase activity was calculated by: 
[(Ac − At) (Ac)]⁄  × 100 
Where Ac 
Where Control OD is the optical density of heated control and Test 
OD is the optical density of the heated test sample. 
denotes the absorbance of the control and At denotes the 
absorbance of the test sample. 
Membrane stabilization assay 
Preparation of human red blood cell (HRBC) suspension  
Blood was collected (approval number ICT/IAEC/2017/P59) and 
taken into heparinized centrifugation tubes. The blood was mixed with 
sterile Alsever’s solution in equal proportion. The resulting mixture 
was then centrifuged at 3000 rpm for 10 min. The supernatant plasma 
was removed, and the erythrocyte sediment was washed thrice with 
normal saline. The blood was reconstituted with isotonic phosphate 
buffer, whose pH was adjusted to 7.4, and a 10% v/v human red blood 
cell (HRBC) suspension was prepared [15]. 
Heat-induced haemolysis 
Different concentrations of SA (10, 20, 40, 60, 80 and 100 µg/ml) were 
prepared in isotonic phosphate buffered solution. The reaction mixture 
consisted of 5 ml of the test drug solution and 0.1 ml of HRBC 
suspension. The control tube composed of 5 ml of the vehicle (isotonic 
phosphate buffer) and the standard tube consisted of 5 ml of diclofenac 
sodium (prepared in isotonic phosphate buffer at concentrations of 100 
and 200 µg/ml). To each of the control and standard tube were added 
0.1 ml of HRBC suspension. All of the tubes were then incubated at 56 °C 
for a duration of 30 min. After the incubation period, the tubes were 
allowed to cool to room temperature, followed by centrifugation at 3000 
rpm for 5 min. The spectrophotometer was used to measure the 
absorbance of the supernatant at 540 nm. The assay was performed in 
triplicates [15, 16].  
Percentage inhibition of heat-induced haemolysis was calculated by:  
[(Control OD − Test OD) ⁄ (Control OD)] × 100 
Hypotonicity-induced haemolysis 
SA was dissolved in distilled water to prepare the different 
concentration of the test sample (10, 20, 40, 60, 80 and 100 µg/ml). 
The reaction mixture consisted of 5 ml of the test sample, to which 
was added 0.1 ml of HRBC suspension. The control tubes contained 5 
ml of distilled water, and the standard tube contained diclofenac 
sodium dissolved in distilled water to obtain the concentrations of 
100 µg/ml and 200 µg/ml. To each of the control and standard tube 
were added 0.1 ml of HRBC suspension. The reaction mixture was 
incubated at 37 °C for 1 h, followed by centrifugation at 3000 rpm 
for 5 min. The spectrophotometer was used to measure the 
absorbance of the supernatant at 540 nm. The assay was performed 
in triplicates [15].  
Percentage inhibition of hypotonicity-induced haemolysis was 
calculated by:  
[(Control OD − Test OD) ⁄ (Control OD)] × 100 
Where Control OD is the optical density of hypotonic control and 
Test OD is the optical density of the hypotonic test sample. 
Statistical analysis 
Data obtained are expressed as the mean±standard deviation (SD) 
(n=3). The half-maximal inhibitory concentration (IC50)  
RESULTS AND DISCUSSION 
value was 
calculated using the linear regression analysis. 
Protein denaturation is a well-known cause of inflammation. 
Denaturation of a protein involves the disruption of the tertiary and 
secondary structure of the proteins caused by the application of 
external stress, leading to loss of its biological function [14, 17]. The 
transformation of protein from soluble to an insoluble form is 
known as denaturation [18]. The mechanism of denaturation 
involves the change in disulphide and hydrogen bonds, along with an 
alteration in the hydrophobic and electrostatic forces of attraction 
[19]. As part of the investigation on the mechanism of the anti-
inflammation activity, the ability of SA to inhibit protein 
denaturation was studied. The inhibition of protein denaturation by 
SA was produced in a dose-dependent manner. The IC50
Neutrophils play an important role in the pathogenesis of 
inflammation that release mediators such as serine proteinases 
localized in the lysosomes. These leukocyte proteinases act as key 
participants in the development of tissue damage. Inhibition of these 
proteinases has suggested the anti-inflammatory action of drugs [20, 
21]. SA showed inhibition of proteinase activity in a concentration-
dependent manner. The IC
 value of SA 
was found to be 49.38±0.56 µg/ml. SA at 100 µg/ml exhibited 
comparable protein denaturation inhibition with that of the 
standard drug, aspirin (table 1).  
50
 
 value of SA was calculated to be 
53.73±0.27 µg/ml. SA at a concentration of 100 µg/ml showed 
inhibition of proteinase activity similar to aspirin (table 1). 
Table 1: Effect of syringic acid on protein denaturation, proteinase inhibition, and membrane stabilization assay 
 
 











10 31.12±1.23 9.020±0.25 35.53±0.98 17.91±0.94 
20 35.91±0.78 18.39±0.81 35.71±1.55 44.17±1.43 
40 45.50±0.29 37.13±0.89 46.69±1.87 48.65±1.76 
60 55.09±1.14 55.87±0.97 66.42±0.67 57.61±0.69 
80 64.68±0.97 74.61±1.18 86.24±0.82 88.76±0.38 
100 74.26±0.87 93.35±0.52 117.92±0.56 118.44±1.34 
Aspirin 100 87.46±0.40 92.44±0.31 ---- ---- 
Diclofenac Sodium 200 ---- ---- 69.47±0.76 77.57±0.31 
IC50 ----  (µg/ml) 49.38±0.56 53.73±0.27 57.13±0.24 53.87±0.72 
Correlation coefficient (r) ---- 0.978 0.998 0.997 0.967 
Values are expressed as mean±SD (n=3). Linear regression analysis was used to calculate the IC50 values. 
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The HRBC membrane stabilization assay is used as a method to 
study the in vitro anti-inflammatory activity of potential compounds 
because the red blood cell membrane is analogous to the lysosomal 
membrane [22-24]. One of the limiting steps in the process of 
inflammatory response is the stabilization of the lysosomal 
membrane, which would prevent the release of lysosomal 
constituents of activated neutrophil such as bactericidal enzymes 
and proteases, leading to further tissue inflammation and damage 
upon extracellular release [25, 26]. The haemolysis of red blood cell 
can be induced by heat as well as hypotonicity. In hypotonicity-
induced haemolysis, thereby occurs shrinkage of cells, characterized 
by the release of intracellular electrolytes and fluid components that 
takes place as a result of osmotic loss [27]. SA has shown to inhibit the 
haemolysis triggered by both heat and hypotonicity in a dose-
dependent manner probably owing to the ability of SA to stabilize the 
membranes. This action may be attributed to the anti-inflammatory 
activity of SA. The heat-induced haemolysis was inhibited by SA with 
an IC50 value of 57.13±0.24 µg/ml. On the other hand, SA showed 
inhibition of hypotonicity-induced with an IC50 
CONCLUSION 
value of 53.87±0.72 
µg/ml. SA exhibited comparable anti-inflammatory activity as that of 
the standard drug, diclofenac sodium (table 1).  
Our results indicated that SA possesses anti-inflammatory 
properties in vitro. The results of the present study are consistent 
with the findings of previous studies that have reported similar 
observations with regards to the anti-inflammatory activity of the 
plant extracts containing SA [28, 29]. 
In conclusion, the present preliminary study using in vitro anti-
inflammatory assays suggested that SA has potential anti-
inflammatory and anti-arthritic effects. Further work can be done on 
testing the anti-inflammatory activity of SA using in vivo models and 
studying its underlying mechanism of action. 
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